India stiff-arms CRL app for Bristol-Myers' Sprycel; Adcock board OKs $1.3B takeover by CFR;

@FiercePharma: China's state TV broadcasts corruption allegations against Sino Biopharm, first domestic drugmaker publicly tagged in bribery probe. | Follow @FiercePharma

@CarlyHFierce: Second recall in as many weeks for J&J--this time, a moldy schizophrenia drug is the culprit. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> India's patent office rejected Mumbai-based BDR Pharmaceuticals' application for a compulsory license on Bristol-Myers Squibb's ($BMY) cancer drug Sprycel. Report

> South Africa-based Adcock Ingram said its board approved a $1.3 billion buyout offer from Chile's CFR Pharmaceuticals after CFR pledged to move jobs to South Africa. Report

> Amgen ($AMGN) said researchers found new biomarkers that can predict a lack of response to its cancer treatment Vectibix, which could help target the drug to the right patients. Report

> MiMedx, a company that makes injectable treatments from placental tissue, has drawn scrutiny from the FDA, which questions whether the company's products require more agency oversight. Report (sub. req.)

Medical Device News

@FierceMedDev: Gore's endovascular graft-repair device gains wider FDA nod. Item | Follow @FierceMedDev

@DamianFierce: St. Jude is riding into India with a new pacemaker and a plan to boost sales. Story | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Civitas corrals $38M for inhaled Parkinson's treatment. More from FierceDrugDelivery | Follow @MichaelGFierce

> Ariosa targets Brazil with prenatal Dx. Article

> InVivo slides again as CFO bolts, spinal study pends. Report

> J&J feels Decision Diagnostics' sting in glucose strip patent fight. News

Biotech News

@FierceBiotech: ICYMI yesterday--Industry Voices: Breakthrough designation Q&A via Michelle Rohrer. Commentary | Follow @FierceBiotech

@JohnCFierce: I think the patient perspective many news orgs have fundamentally corrupts coverage of animal studies. Article | Follow @JohnCFierce

@EmilyMFierce: Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. More from FierceBiotech Research | Follow @EmilyMFierce

@Ry_McBride: I'm talking to Treato (social listening for pharma) later today. Stay tuned for post at FierceBiotech IT. | Follow @Ry_McBride

> Gilead leaps ahead with FDA app for PI3K cancer killer. More

> Biotech R&D spending roars ahead as Big Pharma grimly holds the line. Article

> Sanofi cancels diabetes drug pitch--for now--as GLP-1 competition races ahead. Story

> GlaxoSmithKline's great, terrible, wonderful, not-so-good year. Article

Pharma Manufacturing News

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. Story | Follow @EricPFierce

> J&J recall streak continues with moldy schizophrenia drug. News

> Eisai U.K. site OK'd to make Fycompa. Report

> Merged CFR, Adcock Ingram to have 18 manufacturing sites. Article

> KKR deal in Gland Pharma calls for $100M plant investment. Item

> Pharma packaging growing market with openings for good ideas. More

Vaccines News

> Meningitis cases fall 94% following vaccine introduction. Report

> Low uptake of Merck's Zostavax costing healthcare systems. Item

> Early-phase HIV vaccines advance on positive data. News

> Implant aims to end logistical challenges of cancer vaccines. More

> Pfizer details plans to expand vaccine portfolio beyond Prevnar. Article

> PhIII data dents GSK's hopes for cancer vaccine. Story

And Finally... Middle-aged men need estrogen to fight a spreading waistline, a study found. Report (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.